A St. Louis Park woman with Stage 4 pancreatic cancer has been granted special permission to run or walk the last three quarters of a mile of the Boston Marathon so that she can complete the final stretch that she couldn't finish last year because of the terrorist explosions.
The Star Tribune reports that Elinor Scott was in the last mile of the race last year when the bombs went off, robbing her of her long-held dream of completing the famed course.
FOX 9 also profiled the 51-year-old mother of four, who was diagnosed with pancreatic cancer in January; it's one of the cancers with the bleakest outcomes. Scott wants to finish the race with her teenage daughter Martha Sutter, who accompanied her last year and was just yards away from where the blast went off.
“I was just kind of shocked that something like this could happen at such an event of such joy and happiness and dreams coming true for my mom,” Martha Sutter told WCCO.
Now they plan to go back to Boston together. While surgery and chemotherapy have left Scott too frail to train for the race, she is eager to cross the finish line Boylston Street with her daughter by her side.
"If they allow it, I'll have her walk it with me, and if they don't, I'll have her waiting there for me," Scott said. "Either way, it's important to both of us."
“I’m very proud of my mom through everything she’s been through, everything she’s overcome,” said Sutter.
A friend and a member of Scott's running club approached David McGillivray, director of the Boston Marathon and told him her story. After clearing it with the marathon’s board of directors and Boston police, McGillivray told Scott that she could walk the final mile.
Her doctors have approved her plan and her mother, Donna Scott, proclaimed it “good medicine.’’
“I’m hoping I’ll be able to at least run the last little bit,’’ said Scott, who began a second round of aggressive chemotherapy on April 2. “Running across the finish line would be my goal.’’
After her current round of chemotherapy, Scott plans to participate in trials for a new drug, Minnelide, being developed at the University of Minnesota.